Tatva Chintan Pharma Chem (TATVA) — Board Meeting

1 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approves director reappointments and Q1 FY26 financial results

🔄 What Changed
Re-appointment of three directors for 2027-2030 terms; approval of capacity expansion and borrowing limit increase to Rs. 1,000 crores

🔮 What's Next
Re-appointments require shareholder approval at the upcoming AGM

💡 Investor Takeaway
Shareholders must approve director reappointments and capital changes at the upcoming AGM, which may impact governance continuity and growth plans.

Tatva Chintan Pharma Chem announced its Q1 FY26 unaudited financial results and reappointed three directors for three-year terms starting 1 February 2027, subject to shareholder approval at the upcoming AGM. The board also approved a capacity expansion at its new Dahej-III facility and increased borrowing limits to Rs. 1,000 crores. The filing includes auditor review reports confirming compliance with SEBI disclosure norms.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approves reappointments, capacity expansion, and increased borrowing limits

🔄 What Changed
Reappointments of three directors for three-year terms; capacity expansion at Dahej; borrowing limit raised to Rs. 1,000 crores

🔮 What's Next
Reappointments subject to shareholder approval at AGM; capacity expansion to meet market demand; borrowing increase requires shareholder approval

💡 Investor Takeaway
Shareholders must approve director reappointments and capital changes at the upcoming AGM.

Tatva Chintan Pharma Chem Limited announced the outcome of its board meeting held on 17 July 2026, approving unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, reappointing three directors for three-year terms starting 1 February 2027, expanding manufacturing capacity at a new greenfield unit in Dahej, and increasing borrowing limits to Rs. 1,000 crores. The board also disclosed related regulatory filings and auditor review reports.

📊 Stock Analysis — TATVA ✨ Ask AI About This

About Tatva Chintan Pharma Chem Limited (TATVA)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

Market Cap: ₹3,079.1 Cr P/E: 215.4

View full TATVA stock details →

📡 Get AI alerts when TATVA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track TATVA — Free

💡 Ask AI about this filing

"What is the expected revenue impact of the new Dahej-III capacity expansion?" "How will the increased borrowing limit affect the company's debt-to-equity ratio?" "What is the projected timeline for achieving full operational capacity at Dahej-III?"

Ask AI Free →

📊 More TATVA filings

See all TATVA filings →

🔥 Also filed on 17 July 2026

WIPRO Wipro Limited Financial Results TATAELXSI Tata Elxsi Limited Financial Results TATATECH Tata Technologies Limited Financial Results JAYNECOIND Jayaswal Neco Industries Limited Financial Results FEDERALBNK The Federal Bank Limited Corporate Action UYFINCORP U. Y. Fincorp Limited Insider Trading

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TATVA files new disclosures

Track TATVA filings, board meetings, and corporate actions. Free email alerts at 5 PM.